Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosis and Classification

Authored by Sourabh Sharma, published on 2026-11-18 17:53:44.0

  1. Unexplained Proteinuria, Haematuria, AKI/CKD, or eGFR Decline With Suspected Monoclonal Gammopathy
    • Obtain SPEP/SIFE, UPEP/UIFE, Serum FLC, Proteinuria Quantification, Urine Microscopy, Renal Function, and Relevant Biochemistry
      • Do Serum or Urine Studies Detect a Monoclonal Protein?
        • Does Renal Phenotype Warrant Biopsy, and Is Biopsy Safe?
          • Obtain Kidney Biopsy; Ensure LM, IF, EM, and Congo Red
            • Does Integrated Pathology Identify an MGRS-Compatible Lesion?
              • Classify Lesion by Deposit Composition and Ultrastructure
                • Organized Deposits: AL/AH/AHL Amyloidosis, Immunotactoid, Type I Cryoglobulinaemic, or Monotypic Fibrillary GN
                  • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                    • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                      • Manage Through the Relevant Overt Haematological Malignancy Pathway
                      • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                        • Confirm and Classify MGRS by Renal Lesion and Clone
                        • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                        • Classify Coincidental MGUS With Unrelated Kidney Disease
                        • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                • Nonorganized Deposits: MIDD, PGNMID, or Monoclonal Membranous Patterns
                  • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                    • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                      • Manage Through the Relevant Overt Haematological Malignancy Pathway
                      • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                        • Confirm and Classify MGRS by Renal Lesion and Clone
                        • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                        • Classify Coincidental MGUS With Unrelated Kidney Disease
                        • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                • Tubular or Crystalline Lesions: Cast Nephropathy, LCPT, or Crystal-Storing Disease
                  • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                    • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                      • Manage Through the Relevant Overt Haematological Malignancy Pathway
                      • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                        • Confirm and Classify MGRS by Renal Lesion and Clone
                        • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                        • Classify Coincidental MGUS With Unrelated Kidney Disease
                        • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                • Indirect or Sparse-Deposit Lesions: C3 Glomerulopathy or TMA
                  • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                    • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                      • Manage Through the Relevant Overt Haematological Malignancy Pathway
                      • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                        • Confirm and Classify MGRS by Renal Lesion and Clone
                        • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                        • Classify Coincidental MGUS With Unrelated Kidney Disease
                        • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
              • Do Reference-Centre Proteomics or Ancillary IF Establish Deposit Identity?
                • Classify Lesion by Deposit Composition and Ultrastructure
                  • Organized Deposits: AL/AH/AHL Amyloidosis, Immunotactoid, Type I Cryoglobulinaemic, or Monotypic Fibrillary GN
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Nonorganized Deposits: MIDD, PGNMID, or Monoclonal Membranous Patterns
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Tubular or Crystalline Lesions: Cast Nephropathy, LCPT, or Crystal-Storing Disease
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Indirect or Sparse-Deposit Lesions: C3 Glomerulopathy or TMA
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                • Classify as Indeterminate; Reassess or Repeat Biopsy if Disease Evolves
              • Treat Alternative Biopsy Diagnosis; Classify Gammopathy Independently
          • Do Not Diagnose MGRS; Monitor and Reassess Biopsy Need
        • Apply CKD- and Assay-Adjusted FLC Interpretation; Proceed if Suspicion Persists
          • Does Renal Phenotype Warrant Biopsy, and Is Biopsy Safe?
            • Obtain Kidney Biopsy; Ensure LM, IF, EM, and Congo Red
              • Does Integrated Pathology Identify an MGRS-Compatible Lesion?
                • Classify Lesion by Deposit Composition and Ultrastructure
                  • Organized Deposits: AL/AH/AHL Amyloidosis, Immunotactoid, Type I Cryoglobulinaemic, or Monotypic Fibrillary GN
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Nonorganized Deposits: MIDD, PGNMID, or Monoclonal Membranous Patterns
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Tubular or Crystalline Lesions: Cast Nephropathy, LCPT, or Crystal-Storing Disease
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Indirect or Sparse-Deposit Lesions: C3 Glomerulopathy or TMA
                    • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                      • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                        • Manage Through the Relevant Overt Haematological Malignancy Pathway
                        • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                          • Confirm and Classify MGRS by Renal Lesion and Clone
                          • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                          • Classify Coincidental MGUS With Unrelated Kidney Disease
                          • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                • Do Reference-Centre Proteomics or Ancillary IF Establish Deposit Identity?
                  • Classify Lesion by Deposit Composition and Ultrastructure
                    • Organized Deposits: AL/AH/AHL Amyloidosis, Immunotactoid, Type I Cryoglobulinaemic, or Monotypic Fibrillary GN
                      • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                        • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                          • Manage Through the Relevant Overt Haematological Malignancy Pathway
                          • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                            • Confirm and Classify MGRS by Renal Lesion and Clone
                            • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                            • Classify Coincidental MGUS With Unrelated Kidney Disease
                            • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                    • Nonorganized Deposits: MIDD, PGNMID, or Monoclonal Membranous Patterns
                      • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                        • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                          • Manage Through the Relevant Overt Haematological Malignancy Pathway
                          • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                            • Confirm and Classify MGRS by Renal Lesion and Clone
                            • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                            • Classify Coincidental MGUS With Unrelated Kidney Disease
                            • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                    • Tubular or Crystalline Lesions: Cast Nephropathy, LCPT, or Crystal-Storing Disease
                      • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                        • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                          • Manage Through the Relevant Overt Haematological Malignancy Pathway
                          • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                            • Confirm and Classify MGRS by Renal Lesion and Clone
                            • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                            • Classify Coincidental MGUS With Unrelated Kidney Disease
                            • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                    • Indirect or Sparse-Deposit Lesions: C3 Glomerulopathy or TMA
                      • Perform Marrow Aspirate/Biopsy, Flow, FISH/Cytogenetics, and Clone-Directed Imaging
                        • Are Myeloma, WM, CLL, Lymphoma, or Other Overt Malignancy Criteria Met?
                          • Manage Through the Relevant Overt Haematological Malignancy Pathway
                          • Assess Three-Way Concordance: Clone or Protein, Renal Lesion, and Causality
                            • Confirm and Classify MGRS by Renal Lesion and Clone
                            • Diagnose MGRS-Compatible Lesion With Clone Not Detected
                            • Classify Coincidental MGUS With Unrelated Kidney Disease
                            • Repeat Targeted Monoclonal and Pathology Studies With Expert Review
                  • Classify as Indeterminate; Reassess or Repeat Biopsy if Disease Evolves
                • Treat Alternative Biopsy Diagnosis; Classify Gammopathy Independently
            • Do Not Diagnose MGRS; Monitor and Reassess Biopsy Need
  2. Do Not Diagnose MGRS From CKD Plus M-Protein Alone
  3. Negative Studies Do Not Exclude MGRS; Escalate to Reference-Centre Testing
tosprivacy